Drugs that contain Testosterone Undecanoate
1. Aveed patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7718640 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(2 years from now) | |
| US8338395 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 05, 2017 |
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: INJECTABLE;INTRAMUSCULAR
AVEED family patents
2. Jatenzo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11179402 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Apr, 2026
(1 year, 11 months from now) | |
| US10617696 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11331325 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Jan, 2027
(2 years from now) | |
| US8241664 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Mar, 2029
(4 years from now) | |
| US11426416 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US10543219 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US8778916 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US11179403 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(5 years from now) | |
| US8492369 | TOLMAR | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Dec, 2030
(6 years from now) | |
| US11564933 | TOLMAR | Methods of treating testosterone deficiency |
Apr, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 27, 2022 |
Market Authorisation Date: 27 March, 2019
Treatment: Method of treating testosterone deficiency; A method of treating testosterone deficiency in men; Testosterone replacement therapy in males for conditions associated with a deficiency or absence of end...
Dosage: CAPSULE;ORAL
JATENZO family patents
3. Kyzatrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576089 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| US11590146 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| US10576090 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| US11617758 | MARIUS PHARMS LLC | Emulsion formulations |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2025 |
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE;ORAL
KYZATREX family patents
4. Tlando patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778922 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(4 years from now) | |
| US11304960 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(4 years from now) | |
| US8865695 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(4 years from now) | |
| US9949985 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US10716794 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US11433083 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US10226473 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US9943527 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US11311555 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US11364249 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
| US11559530 | ANTARES PHARMA INC | Oral testosterone undecanoate therapy |
Nov, 2037
(13 years from now) | |
| US11464735 | ANTARES PHARMA INC | Fixed dose oral testosterone undecanoate compositions and use thereof |
Apr, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2025 |
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE;ORAL
TLANDO family patents